Annovis Bio, INC 10-Q quarterly reports

Annovis Bio reports a net loss of $17.6 million for Q1 2026 as it advances its lead neurodegeneration candidate, buntanetap, through pivotal clinical trials.

Annovis Bio reported increased net losses and cash burn for Q3 2025, raising substantial doubt about its ability to continue as a going concern, despite positive clinical trial data and recent capital raises.

Annovis Bio, a clinical-stage biopharmaceutical company, reported increased net losses and significant cash burn, raising substantial doubt about its ability to continue as a going concern despite progress in its neurodegeneration drug trials.

Annovis Bio reports its Q1 2025 financial results, highlighting ongoing clinical trials and recent FDA interactions.

Annovis Bio's Q3 2024 report details a net loss of $12.6 million, a decrease in research and development expenses, and updates on their clinical trials for Alzheimer's and Parkinson's disease.

Annovis Bio's Q2 2024 report highlights continued clinical trial progress for Buntanetap, alongside a net loss and ongoing efforts to secure additional funding.

Annovis Bio reports a net loss of $1.1 million for the first quarter of 2024 and expresses substantial doubt about its ability to continue as a going concern.